{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:32:38Z","timestamp":1783632758678,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF16OC0022632"],"award-info":[{"award-number":["NNF16OC0022632"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Foundation of the Capital Region of Denmark"},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["12-126045"],"award-info":[{"award-number":["12-126045"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Augustinus Foundation"},{"name":"The Kirsten and Freddy Johansen\u2019s Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11102-022-01297-x","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:04:04Z","timestamp":1673028244000},"page":"152-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct02005978","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nanna Thurmann","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine M\u00f8ller","family":"Erichsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Buus","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Idorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-0821","authenticated-orcid":false,"given":"Marianne","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"1297_CR1","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1210\/jcem-27-10-1418","volume":"27","author":"PH S\u00f6nksen","year":"1967","unstructured":"S\u00f6nksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JD (1967) Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 27:1418\u20131430","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fendo.2018.00358","volume":"9","author":"F Ferra\u00f9","year":"2018","unstructured":"Ferra\u00f9 F, Albani A, Ciresi A, Giordano C, Cannav\u00f2 S (2018) Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol (Lausanne) 9:358","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1297_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102\u2013152","journal-title":"Endocr Rev"},{"key":"1297_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","volume":"52","author":"S Kasayama","year":"2000","unstructured":"Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549\u2013555","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1297_CR5","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","volume":"34","author":"A Kreze","year":"2001","unstructured":"Kreze A, Kreze-Spirova E, Mikulecky M (2001) Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34:1429\u20131433","journal-title":"Braz J Med Biol Res"},{"key":"1297_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00592-009-0112-9","volume":"46","author":"E Resmini","year":"2009","unstructured":"Resmini E, Minuto F, Colao A, Ferone D (2009) Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 46:85\u201395","journal-title":"Acta Diabetol"},{"key":"1297_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","volume":"17","author":"O Alexopoulou","year":"2014","unstructured":"Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17:81\u201389","journal-title":"Pituitary"},{"key":"1297_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27:470\u2013483","journal-title":"Trends Endocrinol Metab"},{"key":"1297_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11892-017-0838-7","volume":"17","author":"AM Hannon","year":"2017","unstructured":"Hannon AM, Thompson CJ, Sherlock M (2017) Diabetes in patients with acromegaly. Curr Diab Rep 17:8","journal-title":"Curr Diab Rep"},{"key":"1297_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500\u20131508","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR11","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98:3446\u20133453","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR12","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1210\/jc.2006-2276","volume":"92","author":"R Lindberg-Larsen","year":"2007","unstructured":"Lindberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jorgensen JO (2007) The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724\u20131728","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR13","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1210\/jc.2005-0531","volume":"90","author":"JO Jorgensen","year":"2005","unstructured":"Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627\u20135631","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR14","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM (2019) Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104:2892\u20132902","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR15","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1210\/jcem.85.10.6870","volume":"85","author":"G Barrande","year":"2000","unstructured":"Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J (2000) Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779\u20133785","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1530\/EJE-10-1105","volume":"164","author":"CL Ronchi","year":"2011","unstructured":"Ronchi CL, Verrua E, Ferrante E, Bender G, Sala E, Lania AG, Fassnacht M, Beck-Peccoz P, Allolio B, Spada A, Arosio M (2011) Long-term effects of radiotherapy on cardiovascular risk factors in acromegaly. Eur J Endocrinol 164:675\u2013684","journal-title":"Eur J Endocrinol"},{"key":"1297_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"JJ Holst","year":"2009","unstructured":"Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127\u2013136","journal-title":"Mol Cell Endocrinol"},{"key":"1297_CR18","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696\u20131705","journal-title":"Lancet"},{"key":"1297_CR19","doi-asserted-by":"publisher","first-page":"E832","DOI":"10.1152\/ajpendo.00700.2009","volume":"298","author":"KJ Hare","year":"2010","unstructured":"Hare KJ, Vilsb\u00f8ll T, Holst JJ, Knop FK (2010) Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 298:E832-837","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1297_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1210\/jcem-60-1-120","volume":"60","author":"T Krarup","year":"1985","unstructured":"Krarup T, Madsbad S, Moody AJ (1985) Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent) diabetes mellitus. J Clin Endocrinol Metab 60:120\u2013125","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR21","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1210\/jc.2011-0266","volume":"96","author":"O Lindgren","year":"2011","unstructured":"Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A, Ahren B (2011) Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 96:2519\u20132524","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1530\/eje.0.1300581","volume":"130","author":"BL Koop","year":"1994","unstructured":"Koop BL, Harris AG, Ezzat S (1994) Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 130:581\u2013586","journal-title":"Eur J Endocrinol"},{"key":"1297_CR23","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1210\/jcem.87.4.8432","volume":"87","author":"C Parkinson","year":"2002","unstructured":"Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ (2002) A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87:1797\u20131804","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR24","doi-asserted-by":"publisher","first-page":"E1081","DOI":"10.1152\/ajpendo.00239.2019","volume":"317","author":"SL Jepsen","year":"2019","unstructured":"Jepsen SL, Grunddal KV, Wewer Albrechtsen NJ, Engelstoft MS, Gabe MBN, Jensen EP, \u00d8rskov C, Poulsen SS, Rosenkilde MM, Pedersen J, Gribble FM, Reimann F, Deacon CF, Schwartz TW, Christ AD, Martin RE, Holst JJ (2019) Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice. Am J Physiol Endocrinol Metab 317:E1081-e1093","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1297_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.peptides.2015.03.011","volume":"67","author":"B Ahr\u00e9n","year":"2015","unstructured":"Ahr\u00e9n B (2015) Glucagon\u2014early breakthroughs and recent discoveries. Peptides 67:74\u201381","journal-title":"Peptides"},{"key":"1297_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","volume":"24","author":"A Segerstolpe","year":"2016","unstructured":"Segerstolpe A, Palasantza A, Eliasson P, Andersson EM, Andreasson AC, Sun X, Picelli S, Sabirsh A, Clausen M, Bjursell MK, Smith DM, Kasper M, Ammala C, Sandberg R (2016) Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab 24:593\u2013607","journal-title":"Cell Metab"},{"key":"1297_CR27","first-page":"74","volume":"10","author":"R Gao","year":"2021","unstructured":"Gao R, Yang T, Zhang Q (2021) \u03b4-Cells: the neighborhood watch in the islet community. Biology (Basel) 10:74","journal-title":"Biology (Basel)"},{"key":"1297_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molmet.2018.05.017","volume":"15","author":"M Gannon","year":"2018","unstructured":"Gannon M, Kulkarni RN, Tse HM, Mauvais-Jarvis F (2018) Sex differences underlying pancreatic islet biology and its dysfunction. Mol Metab 15:82\u201391","journal-title":"Mol Metab"},{"key":"1297_CR29","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/jdi.12829","volume":"9","author":"I Horie","year":"2018","unstructured":"Horie I, Abiru N, Eto M, Sako A, Akeshima J, Nakao T, Nakashima Y, Niri T, Ito A, Nozaki A, Haraguchi A, Akazawa S, Mori Y, Ando T, Kawakami A (2018) Sex differences in insulin and glucagon responses for glucose homeostasis in young healthy Japanese adults. J Diabetes Investig 9:1283\u20131287","journal-title":"J Diabetes Investig"},{"key":"1297_CR30","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2006-0524","volume":"91","author":"H Filipsson","year":"2006","unstructured":"Filipsson H, Monson JP, Koltowska-H\u00e4ggstr\u00f6m M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954\u20133961","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR31","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1210\/jc.2009-1097","volume":"94","author":"M Sherlock","year":"2009","unstructured":"Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216\u20134223","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"1297_CR32","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.2337\/dc11-s227","volume":"34","author":"JJ Holst","year":"2011","unstructured":"Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S (2011) Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34(Suppl 2):S251-257","journal-title":"Diabetes Care"},{"key":"1297_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46\u201352","journal-title":"Diabetologia"},{"key":"1297_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14461","author":"A Decock","year":"2021","unstructured":"Decock A, Verroken C, Van de Velde F, Vilsb\u00f8ll T, Holst JJ, T\u2019Sjoen G, Lapauw B (2021) In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.14461","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1297_CR35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40:268\u2013332","journal-title":"Endocr Rev"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01297-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T13:15:07Z","timestamp":1675948507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01297-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01297-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"assertion":[{"value":"30 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest that could be perceived as prejudicing the impartiality of the reported research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}